This promising finding suggests that the use of vitamin therapy should be included as an adjunct with anti-VEGF treatment, as no adverse effects of the vitamin therapy have been found, and, if this first finding is supported by larger trials, then such vitamin therapy may become a standard of care included for treating neo-vascular AMD. Here, VEGFA is linked to age-related macular degeneration.